(C) Reuters. JFK Presidential Library celebrates the 50th anniversary of the Moon landing
(Reuters) – U.S-based cancer testing startup Grail Inc, which has received funding from Amazon.com Inc (NASDAQ:AMZN) founder Jeff Bezos, on Wednesday filed for a U.S. initial public offering.
Grail was founded by gene sequencing company Illumina Inc (NASDAQ:ILMN) in 2016, with investments from ARCH Venture Partners, Sutter Hill Ventures and Bezos Expeditions, the venture investment fund of Jeff Bezos.
The company, which is developing a blood test to identify early-stage cancers, has set a placeholder amount of $100 million for the IPO, without disclosing the size of its offering.
Illumina is the majority shareholder in Grail with a 14.6% stake, according to the company’s filing with U.S. securities regulators.
Morgan Stanley (NYSE:MS), Goldman Sachs (NYSE:GS) & Co LLC, and BofA Securities are acting as lead bookrunners for the proposed offering. The company has applied to list its stock on the Nasdaq under the ticker symbol “GRAL”.
Jeff Bezos-backed cancer testing company Grail files for U.S. IPO
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.